Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Takes License to Fundamental Gene-Silencing Patent

Premium

Alnylam Pharmaceuticals this week announced that it has taken a non-exclusive license to RNAi-related intellectual property held by UK technology management firm Plant Bioscience Limited.

As reported by Gene Silencing News, PBL was recently awarded a patent that broadly covers the use of small RNAs to trigger post-transcriptional gene silencing and is based on the pioneering work of the Sainsbury Laboratory researchers David Baulcombe and Andrew Hamilton (GSN 3/8/2012).

PBL, which is jointly owned by the Sainsbury Laboratory, the John Innes Center, and the UK's Biotechnology and Biological Sciences Research Council, has made it a goal to non-exclusively license the intellectual property to as many parties as possible, PBL Managing Director Jan Chojecki said at the time.

The Alnylam deal “endorses the strength of our patent estate in the RNAi field and we look forward to working with other partners through our non-exclusive licensing strategy in agricultural, research, diagnostic, and therapeutic commercial applications,” he said in a statement this week.

Terms of the arrangement were not disclosed.

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.